Why TRT Raised Your Blood Pressure (and How to Fix It)

Your cardiovascular system is a pressure system, and like any pressure system, what goes in has to match what the pipes can handle.

When you add testosterone to that system, three things change at once, and each one pushes pressure in its own direction through its own mechanism. Understanding all three means you can actually fix the right thing instead of guessing.

Start with the full picture. Testosterone is a signaling molecule, and one of the things it signals is the bone marrow to produce more red blood cells. More red blood cells means thicker blood, and thicker blood creates more resistance as it moves through your vessels, and your heart has to push harder to move it, and that push is what you measure as blood pressure. That is the first pathway. The second is water. Testosterone converts to estrogen through a process called aromatization, and estrogen tells your kidneys to hold onto more fluid, and more fluid means more volume in the same set of pipes, and more volume means more pressure. The third is structural. TRT increases total blood volume, and a cardiovascular system that has not been trained to handle higher volume will struggle with the load. Those are your three levers, and each one is pulling in the same direction if you are not managing them.

Now zoom into the first one because it is the biggest driver.

The process is called erythropoiesis, which is your body's red blood cell manufacturing system. Testosterone stimulates it directly, and research from 2008 confirmed that this happens in a linear, dose-dependent way, meaning the more testosterone you take, the more red blood cells your body makes. What you are measuring when you track this is something called hematocrit, which is the percentage of your blood that is made up of red blood cells rather than plasma.

When hematocrit rises, blood viscosity rises with it. Think of the difference between water moving through a hose and honey moving through a hose. The same pump pushing honey needs to generate significantly more force. That force is pressure.

A randomized controlled trial published in 2024 put numbers on this. Men on testosterone whose hematocrit rose more than 6% saw their systolic blood pressure increase by 13.2 mmHg compared to placebo. That is not a small shift. A 13 mmHg increase in systolic is the difference between normal and stage one hypertension by current guidelines.

The clinical threshold worth knowing is 54%. Once hematocrit crosses that level, the evidence supports reducing your dose or pausing therapy until it comes back down. Checking it every six months is not optional if you want to stay ahead of this.

The second mechanism is where most clinics get it wrong.

Testosterone aromatizes, meaning an enzyme in your fat tissue converts some of it into estradiol. Research confirms that testosterone independently increases extracellular water through direct effects on the renal tubules, the structures in your kidneys that decide what to keep and what to excrete. When estradiol is elevated, that fluid retention signal gets amplified, and the extra volume raises pressure the same way filling a balloon past its comfortable limit raises tension in the walls.

The instinct at most clinics is to prescribe an aromatase inhibitor, which is a drug that blocks the enzyme doing the conversion. And that does lower estradiol. The problem is that estradiol is cardiovascular protective, meaning it plays a direct role in keeping vessels flexible and managing inflammatory signals in arterial walls. Animal research has shown that blocking aromatase entirely raises mean arterial pressure, which is the opposite of what you were trying to accomplish.

So the ceiling of estradiol causes a problem, and the floor of estradiol causes a different problem, and you are trying to stay in the middle.

The target range the evidence points toward is 20 to 40 pg/mL on a sensitive estradiol assay. The way to stay there without an aromatase inhibitor is injection frequency. Splitting your weekly dose into smaller, more frequent injections flattens the peaks and troughs of testosterone in your blood, which flattens the peaks and troughs of aromatization, which keeps estradiol steadier. Adjusting the input is more precise than blocking the conversion enzyme, and it does not carry the risk of crashing your estradiol to a level that harms your heart.

The third mechanism does not show up in any blood test.

TRT increases total blood volume. That is simply what it does. Your cardiovascular system is designed to adapt to that kind of change, but adaptation requires a training signal, and that signal is cardio. Aerobic exercise teaches the heart to handle higher stroke volume more efficiently, teaches the vessels to dilate more readily, and reduces resting vascular resistance. Without that stimulus, a larger blood volume moving through an untrained system creates chronic pressure elevation that no lab work will flag and no dose adjustment will fix.

This is not a complex prescription. The cardiovascular system responds to the demand you place on it, and regular aerobic work is the demand that makes it capable of handling what TRT is adding to the system.

Here is where the picture changes.

When those three variables are actually managed, the trajectory of blood pressure on TRT reverses. A study of 737 men on testosterone found that the men who were not on blood pressure medication saw their systolic drop by approximately 12.5 mmHg over the course of treatment. In a separate analysis of 202 men, 33 who had been on antihypertensives were able to discontinue their medication entirely after optimizing their protocol.

TRT in a well-managed protocol does not raise blood pressure chronically. What it does is expose every variable you have not been managing. Uncontrolled hematocrit, unmanaged estradiol, and a cardiovascular system that has never been trained are not problems TRT creates. It is problems TRT reveals by turning up the volume on a system that was already operating with less margin than you realized.

That is actually useful information, because those three things are all fixable.

---

References

1. Olesen TB, Glintborg D, Johnk F, et al. 2024. Blood pressure responses to testosterone therapy are amplified by hematocrit levels in opioid-induced androgen deficiency. Journal of Hypertension, 423, 531-540. Finding: Office SBP increased 6.2 mmHg in testosterone group vs 7.0 mmHg decrease in placebo net 13.2 mmHg. Men with hematocrit rise >6% saw clinically relevant BP increases. Source
2. Coviello AD, Kaplan B, Lakshman KM, et al. 2008. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism, 933, 914-919. Finding: Hemoglobin and hematocrit increased in a linear, dose-dependent fashion. Source
3. Almutlaq RN, Newell-Fugate AE, Evans LC, et al. 2022. Aromatase inhibition increases blood pressure and markers of renal injury in female rats. American Journal of Physiology Renal Physiology, 3232, F170-F181. Finding: Blocking aromatase increased mean arterial pressure. Source
4. Hackett G, Mann A, Haider A, et al. 2024. Testosterone replacement therapy: effects on blood pressure in hypogonadal men. World Journal of Mens Health, 422, 431-443. Finding: Long-term TRT associated with significant SBP and DBP reductions. 33 of 202 men on antihypertensives discontinued them. Source
5. Agrawal P, Singh SM, Kohn T. 2023. Management of erythrocytosis in men receiving testosterone therapy. European Urology Focus, 91, 139-142. Finding: Hematocrit >54% requires dose decrease or discontinuation. Source
6. Johannsson G, Gibney J, Wolthers T, et al. 2005. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. Journal of Clinical Endocrinology and Metabolism, 907, 3891-3896. Finding: Testosterone independently increased extracellular water through renal tubule effects. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness